一分钟看懂
这是一项关于多发性骨髓瘤的I 期研究，登记的药物或干预包括Zirconium Zr 89-DFO-YS5；Positron Emission Tomography / Computed Tomography (PET/CT)；Positron Emission Tomography / Magnetic Resonance Imagin，当前状态为招募中。登记地点显示中国San Francisco有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Zirconium Zr 89-DFO-YS5；Positron Emission Tomography / Computed Tomography (PET/CT)；Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)；Fludeoxyglucose F-18 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of California, San Francisco · San Francisco
公开的入选条件
- * Participants must have histologically or cytologically confirmed multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria
- * At least one positive myelomatous lesion found on 18F-FDG PET/CT or PET/MRI. A positive lesion is defined as uptake greater than liver on FDG PET, based on the Italian myeloma criteria for PET use (IMPeTUs) criteria
- * Age \>= 18 years
- * Total bilirubin =\< 1.5 X institutional upper limit of normal (ULN)
- * Aspartate aminotransferase (AST) =\< 3 X ULN
- * Alanine aminotransferase (ALT) =\< 3 X ULN
- * Creatinine clearance \>= 30 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine \<= 1.5x the institutional upper limit of normal.
- * Ability to understand a written informed consent document, and the willingness to sign it
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05892393；登记信息更新于 2026-09-16。